Potential role of tyrosine kinase inhibitors during primary HIV-1 infection.
a Infectious Diseases Service, Hospital Clínic , University of Barcelona , Barcelona , Spain.
Juan
J
Ambrosioni
b AIDS Immunopathology Unit, National Center of Microbiology , Instituto de Salud Carlos III , Madrid , Spain.
Mayte
M
Coiras
b AIDS Immunopathology Unit, National Center of Microbiology , Instituto de Salud Carlos III , Madrid , Spain.
José
J
Alcamí
a Infectious Diseases Service, Hospital Clínic , University of Barcelona , Barcelona , Spain.
José M
JM
Miró
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000821:virology; D000069439:Dasatinib / Q000627:therapeutic use*; D005786:Gene Expression Regulation; D015658:HIV Infections / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000472:pathogenicity / Q000502:physiology; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D010766:Phosphorylation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D000076106:SAM Domain and HD Domain-Containing Protein 1 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D013997:Time Factors
D019380:Anti-HIV Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; D000076106:SAM Domain and HD Domain-Containing Protein 1; C484280:SAMHD1 protein, human; D000069439:Dasatinib
HIV; TKI; Tyrosine kinase inhibitors; acute/recent infection; dasatinib; primary infection; viral reservoirs